Core Insights - Insulet Corporation reported first-quarter adjusted earnings of $1.02 per share, surpassing the consensus estimate of $0.80 [1] - The company achieved sales of $569 million, reflecting a year-over-year increase of 28.8% (29.8% in constant currency), exceeding the consensus of $543.4 million and the high end of its guidance range [1][2] - Gross margin improved to 71.9%, up 240 basis points, with operating income of $88.8 million, representing 15.6% of revenue, an increase of 270 basis points from the previous year [2] Financial Performance - Adjusted operating income reached $93.5 million, or 16.4% of revenue, up 350 basis points year over year [2] - Adjusted EBITDA was $133.9 million, or 23.5% of revenue, an increase from $89.2 million (20.2% of revenue) a year ago [2] - Total Omnipod revenue was $554.1 million, up 28.0% (29.0% in constant currency), with U.S. Omnipod revenue at $401.7 million, a 26.4% increase [7] Future Guidance - For 2025, Insulet expects revenue growth between 19%-22%, an increase from the prior range of 16%-20% [3] - For Q2 2025, the company forecasts revenue growth between 23% and 26%, with U.S. Omnipod sales projected to increase by 22% to 25% [4] - Omnipod sales are now expected to grow by 20%-23%, up from a previous range of 17%-21% [8] Market Position - Analyst Margaret Kaczor Andrew from William Blair noted that Insulet remains well-positioned in the pump market, which is experiencing rapid adoption among insulin-intensive diabetics in the U.S., leading to margin expansion [5] - The international adoption of pump and Omnipod therapy is expected to drive growth in a market exceeding $7 billion, where current adoption rates are significantly lower than in the U.S. [5] Stock Performance - Insulet's stock (PODD) increased by 17.1%, reaching $301.00 [6]

Core Insights - Insulet reported $569 million in revenue for Q1 2025, marking a year-over-year increase of 28.8% and exceeding the Zacks Consensus Estimate by 4.96% [1] - The company's EPS for the same period was $1.02, up from $0.73 a year ago, resulting in an EPS surprise of 25.93% compared to the consensus estimate of $0.81 [1] Revenue Breakdown - International Omnipod revenue reached $152.40 million, surpassing the average estimate of $144.78 million, with a year-over-year change of +32.2% [4] - U.S. Omnipod revenue was $401.70 million, exceeding the estimated $389.50 million, reflecting a +26.4% change from the previous year [4] - Total Omnipod revenue amounted to $554.10 million, compared to the average estimate of $534.28 million, indicating a +28% year-over-year change [4] - Drug Delivery revenue was reported at $14.90 million, significantly above the average estimate of $7.37 million, with a year-over-year increase of +71.3% [4] Stock Performance - Insulet's shares have returned -0.2% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.93%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of 9.52%.Over the last four quart ...

Revenue Growth - Total revenue for Q1 2025 increased by $127.3 million, or 28.8%, to $569.0 million compared to $441.7 million in Q1 2024, with constant currency revenue growth of 29.8%[83] - U.S. Omnipod revenue rose by $84.0 million, or 26.4%, to $401.7 million in Q1 2025, driven by higher sales volume and customer base growth[84] - International Omnipod revenue increased by $37.1 million, or 32.2%, to $152.4 million in Q1 2025, with a 36.1% increase in constant currency, primarily due to higher volumes from new customers[86] Profitability and Margins - Gross margin improved to 71.9% in Q1 2025, up from 69.5% in Q1 2024, attributed to better manufacturing and supply chain efficiencies[90] - Adjusted EBITDA for Q1 2025 was $133.9 million, compared to $89.2 million in Q1 2024, reflecting improved operational performance[99] - Adjusted EBITDA is used as a supplemental measure for assessing performance, reflecting net income plus significant expenses and transactions[102] Expenses - Research and development expenses for Q1 2025 increased by $9.4 million, or 18.7%, to $59.6 million, reflecting investments in Omnipod and pipeline products[92] - Selling, general and administrative expenses rose by $60.9 million, or 30.5%, to $260.6 million in Q1 2025, mainly due to headcount additions for customer support and business growth[93] Cash Flow and Capital Structure - Free cash flow for the three months ended March 31, 2025, was $51.5 million, down from $65.5 million in the same period of 2024[122] - Cash and cash equivalents increased to $1,283.1 million as of March 31, 2025, compared to $953.4 million at December 31, 2024[107] - Total debt, net, rose to $1,695.4 million as of March 31, 2025, from $1,379.9 million at December 31, 2024, with a debt-to-total capital ratio of 56%[107] - Net cash provided by financing activities was $277.8 million for the three months ended March 31, 2025, compared to a cash outflow of $14.1 million in the same period of 2024[117] Investments and Expenditures - The company entered into a purchase agreement for semiconductor chips worth $71.6 million in 2025[105] - Capital expenditures decreased to $12.3 million for the three months ended March 31, 2025, from $22.1 million in the same period of 2024[115] - Investments in developed software increased to $3.4 million for the three months ended March 31, 2025, compared to $1.9 million in the same period of 2024[116] Shareholder Actions - The company authorized a share repurchase program of up to $125 million through December 31, 2026, to offset dilution from stock-based compensation[111] - The company repurchased $420 million in principal of its Convertible Senior Notes in March and April 2025[108] Future Outlook - The company expects strong U.S. revenue growth for the full year 2025, driven by the recurring revenue model and continued volume growth of Omnipod 5[85] - The company plans to launch Omnipod 5 in nine additional countries, enhancing international market presence and regulatory efforts[78] Taxation - The effective tax rate for Q1 2025 was 26.4%, significantly higher than 6.2% in Q1 2024, primarily due to non-deductible charges and changes in deferred tax asset valuation[97]

Financial Data and Key Metrics Changes - Total company revenue for Q1 2025 was $569 million, representing a 30% year-over-year growth, driven by a 29% increase in total Omnipod growth [21][22] - Gross margin improved to 71.9%, up 240 basis points year-over-year, while adjusted operating margin was 16.4% [34][35] - The company raised its gross margin guidance for the full year to approximately 71% despite an estimated 50 basis point impact from tariffs [43][44] Business Line Data and Key Metrics Changes - U.S. Omnipod revenue grew 26%, exceeding guidance, with strong demand for Omnipod five contributing to this growth [26][27] - New customer starts in the U.S. for Type one and Type two diabetes increased, with over 30% of new starts being Type two [20][21] - International revenue grew 36% above guidance, driven by strong demand for Omnipod five and customer base expansion [31][32] Market Data and Key Metrics Changes - The U.S. market saw a significant increase in healthcare providers prescribing Omnipod five, with nearly 25,000 HCPs now writing scripts, up over 20% from the previous year [30][31] - The company launched Omnipod five in Canada and Switzerland, bringing the total number of international market launches to 13 [32][33] - The international market for Type one diabetes is approximately 3.5 million people, with only 20% to 25% penetration, indicating significant growth potential [99] Company Strategy and Development Direction - The company aims to expand its revenue from $2 billion to $4 billion to $6 billion by focusing on Type one and Type two markets and advancing globalization [12][53] - Strategic priorities include advancing innovation, driving growth in U.S. Type one and Type two populations, and expanding internationally [15][40] - The leadership emphasizes the importance of brand activation and direct-to-consumer strategies to enhance engagement and retention [13][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong first quarter performance and a robust pipeline of innovation [48][49] - The leadership transition is seen as timely, with the new CEO bringing a focus on operational excellence and strategic vision [8][10] - The company anticipates continued strong growth in new customer starts and is optimistic about the adoption of Omnipod five in both Type one and Type two markets [40][41] Other Important Information - The company ended the quarter with approximately $1.3 billion in cash and a $500 million credit facility available, enhancing financial flexibility [37][36] - The board authorized a stock repurchase program of up to $125 million to offset dilution from stock-based compensation [46] Q&A Session Summary Question: What excites you about the role at Insulet and your vision for the business? - The new CEO expressed passion for the diabetes space and highlighted the company's strong momentum and unique position in the market [54][56] Question: Will there be a focus on top-line growth at the expense of margin expansion? - The CEO reassured that the business strategy remains intact, with continued focus on both growth and margin improvement [62] Question: What is the status of the Type two pump adoption in the U.S.? - The management reported strong progress in the Type two launch, with over 30% of new customer starts coming from this segment [65] Question: Can you confirm the strong new start growth in both the U.S. and internationally? - Management confirmed significant strength in new customer starts, both sequentially and year-over-year, driven by the differentiation of Omnipod five [74][75] Question: What are the expectations for gross and operating margin expansion in the coming years? - The management expressed confidence in maintaining industry-leading gross margins while continuing to invest in growth opportunities [78][81] Question: How is the direct-to-consumer advertising performing? - The company reported higher conversion rates from direct-to-consumer advertising efforts, indicating effective engagement strategies [109]

Financial Data and Key Metrics Changes - Revenue for the total company was $569 million, growing 30% year over year, driven by total Omnipod growth of 29% [19][24] - Gross margin was 71.9%, up 240 basis points, primarily due to improved manufacturing and supply chain efficiencies [32][42] - Adjusted operating margin was 16.4% and adjusted EBITDA was 23.5% in the first quarter [33] Business Line Data and Key Metrics Changes - U.S. Omnipod revenue grew 26%, exceeding guidance, with strong demand for Omnipod five [24] - Over 30% of U.S. new customer starts were Type two, indicating successful market penetration [18][63] - International revenue grew 36% above the high end of guidance, driven by strong demand for Omnipod five [29] Market Data and Key Metrics Changes - Estimated global utilization remained stable compared to the prior year, with an annualized retention rate steady in the U.S. and improved slightly internationally [19][20] - The U.S. sales force expansion has increased the number of healthcare providers engaging with Type two patients by over 20% year over year [28][62] Company Strategy and Development Direction - The company aims to expand its market presence in Type one and Type two diabetes, with a focus on innovation and direct-to-consumer strategies [12][14] - The leadership transition is seen as a pivotal moment for driving growth and enhancing operational execution [6][7] - The company plans to leverage its data to improve patient engagement and retention [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong first quarter performance and a robust pipeline of innovation [47][48] - The strategic priorities include advancing innovation, driving growth in U.S. Type one and Type two populations, and expanding internationally [14][40] - Management anticipates continued strong demand trends benefiting from the differentiated Omnipod five platform [38] Other Important Information - The company raised its full-year revenue growth guidance to a range of 19% to 22% [37] - The gross margin guidance for the full year was raised to approximately 71%, despite anticipated tariff impacts [42] - The company has a strong cash position with approximately $1.3 billion in cash and a $500 million credit facility available [35] Q&A Session Summary Question: What excites you about the role and vision for the business? - The new CEO expressed passion for the diabetes space and confidence in the company's unique insulin delivery platform, emphasizing the potential for future value creation [52][54] Question: Will there be a focus on top-line growth at the expense of margin expansion? - The CEO reassured that the business strategy remains intact, with continued focus on double-digit growth and margin improvement [58][60] Question: How is the Type two pump adoption going in the U.S.? - The Type two launch is progressing well, with a significant increase in new customer starts from Type two diabetes [61][63] Question: What are the drivers of strong new customer growth? - The differentiation of Omnipod five and effective direct-to-consumer advertising are key factors driving new customer starts [72][105] Question: What is the outlook for international expansion? - The company plans to launch Omnipod five in the Middle East by early 2026, with ongoing growth in established markets like the U.K. and Germany [91][94]

Financial Performance & Growth - Insulet reported $2.1 billion in revenue for 2024[12] - The company achieved a gross margin of 69.8% in FY 2024, a year-over-year increase of 210 basis points[14] - Insulet's operating margin for FY 2024 was 14.9%, representing a 260 basis points increase year-over-year[14] - The company anticipates revenue growth between 19% and 22% for FY 2025[17] - International Omnipod revenue grew at a CAGR of approximately 17% from 2020 to 2025E, reaching ~$673 million[46] - U S Omnipod revenue grew at a CAGR of approximately 28% from 2020 to 2025E, reaching ~$1.8 billion[43] Omnipod 5 & Market Position - Omnipod is the 1 insulin pump for new pump users in the U S and EU in 2024[12] - Omnipod 5 is the first AID system FDA-cleared for both type 1 and type 2 diabetes in the U S [12] - Omnipod 5 demonstrated a 20%-23% increase in time in range for adults with type 1 and type 2 diabetes, respectively[19] - Approximately 365,000 customers are using Omnipod 5[12]

Exhibit 99.1 Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency ) 1 Raising Full Year Revenue and Gross Margin Guidance ACTON, Mass. - May 8, 2025 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended March 31, 2025. ® "Our first quarter results showcase the strong execution and dedication of the Insulet ...

Core Viewpoint - Wall Street analysts expect Insulet (PODD) to report quarterly earnings of $0.81 per share, reflecting an 11% year-over-year increase, with revenues projected at $541.33 million, a 22.6% increase compared to the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 1.1% in the past 30 days, indicating a reassessment by covering analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenue- Total Omnipod' at $534.28 million, representing a 23.4% increase year-over-year [5]. - 'Revenue- Drug Delivery' is expected to reach $7.37 million, indicating a decline of 15.3% year-over-year [5]. - 'Revenue- International Omnipod' is projected at $144.78 million, reflecting a 25.6% increase year-over-year [5]. - 'Revenue- U.S. Omnipod' is estimated at $389.50 million, showing a 22.6% increase from the prior-year quarter [6]. Stock Performance - Over the past month, Insulet shares have returned +4.8%, outperforming the Zacks S&P 500 composite's +0.4% change [6]. - Currently, Insulet carries a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [6].

Insulet (PODD) shares soared 7.2% in the last trading session to close at $264.72. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.7% gain over the past four weeks.Insulet recorded a strong price rise on investors’ optimism surrounding its impending first-quarter 2025 financial results, which is slated to release on May 8 post the closing bell. The Zacks Consensus Estimate for the first quarter revenue suggests a growth of 22.7 ...